Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

argenx SE

ARGX.BR ✓ COMPLIANT ☆ Track — members

Euronext Brussels · Healthcare · Biotechnology & Medical Research ·

Belgium Large Cap Analyst: BUY

Last Close

$1,060.57

▲ +1.31%

Market Cap $66.14B · Vol 98.42K

Key Metrics

P/E Ratio

40.17

FWD: 30.42

Market Cap

$66.14B

Large Cap

Div Yield

N/A

Annual dividend

EPS Growth

+45.22%

YoY

RSI (14)

78.34

Momentum

Beta

0.76

vs Market

52W High

$1,075.22

2.64% below

52W Low

$660.71

58.10% above

Volume

98.42K

Avg 83.99K

P/B

7.11

Price-to-book

ROE

20.15%

Return on equity

Free Float

99.98%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, argenx SE (ARGX.BR) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does ARGX.BR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.55%

+26.34%

+31.21%

+41.59%

YTD

+27.29%

+49.48%

+105.87%

+209.29%

Financials & Valuation

TTM · Annual

Total Revenue	$4.15B
Net Income	$1.29B
Revenue Growth (YoY)	+59.71%
Gross Margin	89.14%
Operating Margin	25.40%
Net Profit Margin	31.12%
ROE	20.15%
ROA · ROIC	17.18% · 20.08%

P/E Ratio	40.17
Forward P/E (FY1)	30.42
PEG Ratio	0.81
P/S	13.39
P/B	7.11
P/FCF	75.51
EPS Growth	+45.22%
Outstanding Shares	62.56M

Technical Indicators

50-Day SMA	$934.07
200-Day SMA	$846.05
RSI (14)	78.34
Beta	0.76
52-Week High	$1,075.22
52-Week Low	$660.71

Volume Today	98.42K
Avg Daily Volume (30D)	83.99K
Relative Volume	1.17x
Volatility (10D)	32.35
Volatility (30D)	54.38
Free Float	99.98%

Analyst Consensus

BUY

Current Price $1,060.57

Mean Target $1,165.83

52W Low$660.71 52W High$1,075.22

Current

Target

$660.71 $1,075.22

Current Analyst target

+9.92% upside potential · 28 analysts

Identifiers

ExchangeEuronext Brussels

FIGIBBG00GHB88Y8

ISINNL0010832176

CountryNetherlands

Sub-IndustryBio Therapeutic Drugs

Earnings DateOct 22, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

2359.HK WuXi AppTec Co Ltd -0.77% ARGX argenx SE -0.18% INSM Insmed Inc +0.04% 2269.HK WuXi Biologics (Cayman) Inc +2.97% GMAB Genmab A/S +0.57%

Company Profile

argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.